Clinical Endocrinology (1993) 38, 669–675

Author index to Volume 38

Afshar F. see Trainer P.J.
Amiel S. see Cotterill A.M.
Amino N. see Kimura M.
Anderson D.C. see Buckler H.M.
Anderson J.V. see Walker J.D.
Angervo M., Tiihonen M., Leinonen P., Välimäki M. & Seppälä M. Rapid communication Thyroxine treatment increases circulating levels of insulin-like growth factor binding protein-1: a placebo-controlled study 547
Ashley S. see Brada M.
Assies J., Verhoeff N.P.L.G., Bosch D.A. & Hofland L.J. Case of the Month Intracranial dissemination of a macroprolactinoma 539
Astorga R. see Leal-Cerro A.
Atkin S.L. see Masson E.A.
Atkinson A.B. Letter to the Editor Endocrine findings in Cushing's disease 111
Atkinson A.B. see McCance D.R.
Audran M. see Raynaud E.

Bacci V. see Papini E.
Baird D.T. see Tovanabutra S.
Balen A.H., Schachter M.E., Montgomery D., Reid R.W. & Jacobs H.S. Polycystic ovaries are a common finding in untreated female to male transsexuals 325
Barreiro J. see Peñalva A.
Barton J.S., Hindmarsh P.C., Preece M.C. & Brook C.G.D. Blood pressure and the renin-angiotensin-aldosterone system in children receiving recombinant human growth hormone 245
Beardwell C.G. see Dobrashian R.D.
Beauregard H. see Comtois R.
Beedham T. see Williams D.J.
Behrenscheer A. see Juul A.
Bekka S. see Reznik Y.
Belon C. see Lobaccaro J.-M.
Ben-Baruch G. see Schiff E.
Bengtsson B-Å. see Rosén T.
Benker G. see Haase R.
Benn J. see Walker J.D.
Bergmann P. see Heinrichs C.
Berkhout G. see Broekmans F.J.
Bernardus R.E. see Broekmans F.J.
Berta P. see Lobaccaro J.-M.
Bertagna X. see Favrod-Coune C.
Besser G.M. see Trainer P.J.
Besser G.M. see Ure E.
Besser G.M. see Walker J.D.
Betteridge J. see Franklyn J.A.
Bewsher P.D. see MacLeod J.M.
Bigorgne J.C. see Casanova S.
Birkenhäger J.C. see Weber R.F.A.
Bizzarri G. see Papini E.
Bodenner D.L. see Mixson A.J.
Boelaert M. see Moreno-Reyes R.
Boiteau V. see Casanova S.
Bomanji J. see Ure E.
Bomford A. see Cundy T.
Bosaeus I. see Rosen T.
Boscaro M. see Sonino N.
Bosch D.A. see Assies J.
Bottet P. see Reznik Y.
Bouchard P. see Lahlou N.
Bouillon R. see Massa G.
Bourguignon J.P. see Heinrichs C.
Bowden S.J., Hughes S.V. & Ratcliffe W.A. Molecular forms of parathyroid hormone-related protein in tumours and biological fluids 287
Bowes S.B. see Russell-Jones D.L.
Boyers S.P. see Stewart D.R.
Boyle I.T. see Gallacher S.J.
Brada M., Rajan B., Traish D., Ashley S., Holmes-Sellors P.J., Nussey S. & Uttley D. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas 571
Bridges N.A., Hindmarsh P.C., Pringle P.J., Matthews D.R. & Brook C.G.D. The relationship between endogenous testosterone and gonadotrophin secretion 373
Bristow A.F., Gaines-Das R.E., Buttress N., Gallimore J.R., Tennent G.A. & Pepys M.B. The International Standard for Thyroxine Binding Globulin 361
Britton K.E. see Ure E.
Broekmans F.J., Bernardus R.E., Berkhout G. & Schoemaker J. Pituitary responsiveness after administration of a GnRH agonist depot formulation: Decapeptyl CR 579
Brook C.G.D. see Barton J.S.
Brook C.G.D. see Bridges N.A.
Brook C.G.D. see Malhotra A.
Brun J.F. see Raynaud E.
Buckler H.M., Critchley H.O., Cantrill J.A., Shalet S.M., Anderson D.C. & Robertson W.R. Efficacy of low dose purified FSH in ovulation induction following pituitary desensitization in polycystic ovarian syndrome 209
Buckler H.M., Rothwell C., Hollis S. & Robertson W.R. Physiological oestradiol administration does not change the biological to immunological ratio of LH in serum from post-menopausal women 481

Burman K.D. see Solomon B.L.
Butler J. see Cundy T.
Buttress N. see Bristow A.F.

Calmettes C. see Casanova S.
Cantrill J.A. see Buckler H.M.
Carballo A. see Peñalva A.
Carey A.H., Chan K.L., Short F., White D., Williamson R. & Franks S. Rapid communication Evidence for a single gene causing polycystic ovaries and male pattern baldness 653
Caron J. see Casanova S.
Caron J. see Grulet H.
Casanova S., Rosenberg-Bourgin M., Farkas D., Calmettes C., Feingold N., Heshmati H.M., Cohen R., Conte-Devolx B., Guillausseau P.J., Houdent C., Bigorgne J.C., Boiteau V., Caron J. & Modigliani E. Phaeochromocytoma in multiple endocrine neoplasia type 2 531
Casaneuva F.F. see Valcavi R.
Casaneuva F.F. see Leal-Cerro A.
Casaneuva F.F. see Peñalva A.
Cédrin I. see Méchain C.
Celniker A.C. see Stewart D.R.
Chan K.L. see Carey A.H.
Chanal J.L. see Raynaud E.
Chanson P. see Lahlou N.
Chapman M. see Donald R.A.
Chevalier C. see Lobaccaro J.-M.
Christiansen J.S. see Ho K.K.Y.
Clark P.M.S. see Conway G.S.
Cohen R. see Casanova S.
Comtois R., Beauregard H., Hardy J., Robert F. & Somma M. High prolactin levels in patients with Cushing's disease without pathological evidence of pituitary adenoma 601
Conte-Devolx B. see Casanova S.
Conway G.S., Clark P.M.S. & Wong D. Hyperinsulinaemia in the polycystic ovary syndrome confirmed with a specific immunoradiometric assay for insulin 219
Cooke B.A. see Michael A.E.
Corradini M.C.M. see Malerbi D.A.
Cotterill A.M., Holly J.M.P., Amiel S. & Wass J.A.H. Suppression of endogenous insulin secretion regulates the rapid rise of insulin-like growth factor binding protein (IGFBP)-1 levels following acute hypoglycaemia 633
Craen M. see Massa G.
Cragun J.R. see Stewart D.R.
Critchley H.O. see Buckler H.M.
Crombie A.L. see Perros P.
Cundy T., Butler J., Bomford A. & Williams R. Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis 617
Cunha-Neto M.S. see Malerbi D.A.
Curtis P. see Michael A.E.
Czernichow P. see Lobaccaro J.-M.

Darne J.F. see Jones T.H.
Daykin J. see Franklyn J.A.
DeGroot L.J. see Sakurai A.
Delemarre-Van de Waal H.A. Induction of testicular growth and spermatogenesis by pulsatile, intravenous administration of gonadotrophin-releasing hormone in patients with hypogonadotrophic hypogonadism 473
Delemer B. see Grulet H.
Dieguez C. see Leal-Cerro A.
Dieguez C. see Peñalva A.
Dieguez C. see Valcavi R.
Diver M. see Masson E.A.
Dobrashian R.D., O'Halloran D.J., Hunt A., Beardwell C.G. & Shalet S.M. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly 589
Docter R. see Weber R.F.A.
Donald R.A. see Wittert G.A.
Donald R.A., Parry E.G., Wittert G.A., Chapman M., Livesey J.H., Ellis M.J., Evans M.J., Yandle T. & Espiner E.A. The plasma ACTH, AVP, CRH and catecholamine responses to conventional and laparoscopic cholecystectomy 609
Doniach I. Commentary Papillary carcinoma of the thyroid 336
Doniach I. see Walker J.D.
Drury P.L. & Watkins P.J. Review Diabetic renal disease and its prevention 445
Dumas R. see Lobaccaro J.-M.
Duncan A. see MacLeod J.M.
Dunger D.B. see Pal B.R.

Ebner S. & Emerson C.H. Case of the Month Documentation of parathyroid carcinoma fifteen years after resection of a parathyroid 'adenoma' 659
Edge J.A. see Pal B.R.
Edwards C.R.W. see Michael A.E.
El Badawi S. see Moreno-Reyes R.
Ellis M.J. see Donald R.A.
Eltom M. see Moreno-Reyes R.
Emerson C.H. see Ebner S.
Espiner E.A. see Donald R.A.
Espiner E.A. see Wittert G.A.
Evans M.J. see Donald R.A.

Fabbrini R. see Papini E.

Fannin T.F. see McCance D.R.
Farkas D. see Casanova S.
Farquharson M.A. see Gallacher S.J.
Fauser B.C.J.M. see Weber R.F.A.
Fava G.A. see Sonino N.
Favrod-Coune C., Raux-Demay M.C., Proeschel M.F., Bertagna X., Girard F. & Luton J.P. Potentiation of the classic ovine corticotrophin releasing hormone stimulation test by the combined administration of small doses of lysine vasopressin 405
Fédou C. see Raynaud E.
Feingold N. see Casanova S.
Fjellstad-Paulsen A., Höglund P., Lundin S. & Paulsen O. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers 177
Fragoso M.C.B.V. see Malerbi D.A.
Francis R.M. see Scane A.C.
Franklyn J.A. Commentary Thyroid hormone resistance syndromes—are generalized and selective pituitary resistance part of the same disorder? 235
Franklyn J.A., Daykin J., Betteridge J., Hughes E.A., Holder R., Jones S.R. & Sheppard M.C. Thyroxine replacement therapy and circulating lipid concentrations 453
Franks S. see Carey A.H.
Fraser W.D. see Gallacher S.J.

Gaines-Das R.E. see Bristow A.F.
Galifer R.-B. see Lobaccaro J.-M.
Gallacher S.J., Fraser W.D., Farquharson M.A., Logue F.C., McArdle C., Boyle I.T., Nairn E.R. & McNicol A.M. Case of the Month Coincidental occurrence of primary hyperparathyroidism and cancer-associated hypercalcaemia in a middle-aged man 433
Gallimore J.R. see Bristow A.F.
Galron R. see Schiff E.
Gan N. see Wakasugi M.
Georgiadis G. see Tzanela M.
Giammarco V. see Papini E.
Ginsberg J. & Murray P.G. The effects of TSH receptor antibodies on protein kinase C in the thyroid 45
Girard F. see Favrod-Coune C.
Glaser B. see Landau H.
Glasier A.F. see Tovanabutra S.
Goldfarb A. see Landau H.
Gordon D.S. see McCance D.R.
Gross A. see Grulet H.
Grossman A. Commentary New uses for an old peptide: desmopressin and Cushing's syndrome 461
Grossman A. see Walker J.D.
Grossman A.B. see Trainer P.J.
Grossman A.B. see Ure E.
Grulet H., Hecart A.C., Delemer B., Gross A., Sulmont V., Leutenegger M. & Caron J. Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome 621
Guillausseau P.J. see Casanova S.
Guthmann J.-P. see Lobaccaro J.-M.

Haase R., Jaspers C., Schulte H.M., Lancranjan I., Pfingsten H., Orri-Fend M., Reinwein D. & Benker G. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years 165
Hadden D.R. see McCance D.R.
Hagiwara K. see Konno N.
Halkjær-Kristensen see Juul A.
Hamam H.D. see Majeed-Saidan M.A.
Hardy J. see Comtois R.
Harvey R.D. see MacLeod J.M.
Heath D.A. Commentary Parathyroid hormone related protein 135
Hecart A.C. see Grulet H.
Hegedüs L. see Karstrup S.
Heinrichs C. see Massa G.
Heinrichs C., Vis H.L., Bergmann P. & Bourguignon J.P. Rapid communication Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome 647
Heshmati H.M. see Casanova S.
Hess D.L. see Stewart D.R.
Hindmarsh P.C. see Barton J.S.
Hindmarsh P.C. see Bridges N.A.
Hindmarsh P.C. see Malhotra A.
Hindmarsh P.C. see Pal B.R.
Ho K.K.Y., Jorgensen J.O.L., Valiontis E., Waters M.J., Rajkovic I.A. & Christiansen J.S. Different modes of growth hormone (GH) administration do not change GH binding protein activity in man 143
Hofland L.J. see Assies J.
Höglund P. see Fjellstad-Paulsen A.
Holder R. see Franklyn J.A.
Holder R. see Stewart P.M.
Hollis S. see Buckler H.M.
Holly J.M.P. see Cotterill A.M.
Holm H.H. see Karstrup S.
Holmes-Sellors P.J. see Brada M.
Honour J.W. see Rumsby G.
Houdent C. see Casanova S.
Howlett T.A. see Trainer P.J.
Hughes E.A. see Franklyn J.A.
Hughes I.A. see Sakurai A.
Hughes S.V. see Bowden S.J.
Hunt A. see Dobrashian R.D.

Iida F. see Maruyama M.
Illingworth P.J. see Tovanabutra S.
Ismail I.S., Scanlon M.F. & Peters J.R. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback 149
Ito E. see Kimura M.

Jacobs H.S. see Balen A.H.
Jacobs M.L. see Weber R.F.A.
Jaspers C. see Haase R.
Jeffcoate S.L. Review Analytical and clinical significance of peptide hormone heterogeneity with particular reference to growth hormone and luteinizing hormone in serum 113
Jones R.H. see Russell-Jones D.L.
Jones S.R. see Franklyn J.A.
Jones T.H. & Darne J.F. Self-administered subcutaneous human menopausal gonadotrophin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotrophic hypogonadism 203
Jorgensen J.O.L. see Ho K.K.Y.
Joyce B. see Majeed-Saidan M.A.
Juul A., Behrenscheer A., Tims T., Nielsen B., Halkjær-Kristensen J. & Skakkebæk N.E. Rapid communication Impaired thermoregulation in adults with growth hormone deficiency during heat exposure and exercise 237

Karstrup S., Hegedüs L. & Holm H.H. Ultrasonically guided chemical parathyroidectomy in patients with primary hyperparathyroidism: a follow-up study 523
Kelly J.M. see Russell-Jones D.L.
Kendall-Taylor P. see Perros P.
Kennedy L. see McCance D.R.
Khan M. see Majeed-Saidan M.A.
Kimura M., Amino N., Tamaki H., Ito E., Mitsuda N., Miyai K. & Tanizawa O. Gestational thyrotoxicosis and hyperemesis gravidarum: possible role of hCG with higher stimulating activity 345
Kobayashi S. see Maruyama M.
Koizumi K. see Wakasugi M.
Konno N., Yuri K., Taguchi H., Miura K., Taguchi S., Hagiwara K. & Murakami S. Screening for thyroid diseases in an iodine sufficient area with sensitive thyrotrophin assays, and serum thyroid autoantibody and urinary iodide 273
Koutsoyiannis D. see Messinis I.E.
Kuh J.M. see Reznik Y.

La Medica P. see Papini E.
Lahlou N., Le Nestour E., Chanson P., Seret-Bégué D., Bouchard P., Roger M. & Warnet A. Inhibin and follicle-stimulating hormone levels in gonadotroph adenomas: evidence of a positive correlation with tumour volume in men 301
Lancranjan I. see Haase R.
Landau H., Matoth I., Landau-Cordova Z., Goldfarb A., Rachmilewitz E.A. & Glaser B. Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major 55
Landau-Cordova Z. see Landau H.
Lasley B.L. see Stewart D.R.
Lawrie H.S. see Trainer P.J.
Lazarus J.H. Commentary Iodine deficiency and goitre in children in Sudan 17
Lazarus J.H. Commentary Pregnancy, hCG, thyrotoxicosis and hyperemesis gravidarum 343
Le Nestour E. see Lahlou N.
Leal-Cerro A., Pumar A., Villamil F., Astorga R., Dieguez C. & Casanueva F.F. Growth hormone releasing hormone priming increasing growth hormone secretion in patients with Cushing's syndrome 399
Ledger W.L. see Tovanabutra S.
Leinonen P. see Angervo M.
Lemay A. see Méchain C.
Lemonnier D. see Reznik Y.
Leutenegger M. see Grulet H.
Levy A. & Lightman S.L. Review The pathogenesis of pituitary adenomas 559
Liberman B. see Malerbi D.A.
Lightman S.L. see Levy A.
Lindholm J. Letter to the Editor Endocrine findings in Cushing's disease 111
Lindstedt G. see Rosen T.
Livesey J.H. see Donald R.A.
Livesey J.H. see Wittert G.A.
Lobaccaro J.-M., Medlej R., Berta P., Belon C., Galifer R.-B., Guthmann J.-P., Chevalier C., Czernichow P., Dumas R. & Sultan C. PCR analysis and sequencing of the SRY sex determining gene in four patients with bilateral congenital anorchia 197
Logue F.C. see Gallacher S.J.
Lolis D. see Messinis I.E.
London D.R. see Stewart P.M.
Loriaux D.L. see Weber R.F.A.
Lowe D.G. see Trainer P.J.
Lowe D.G. see Walker J.D.
Lowy C. see Walker J.D.
Lundin S. see Fjellstad-Paulsen A.
Luton J.P. see Favrod-Coune C.

MacLeod J.M., McHardy K.C., Harvey R.D., Duncan A., Reid I.W., Bewsher P.D. & Robins S.P. The early effects of radioiodine therapy for hyperthyroidism on biochemical indices of bone turnover 49
Maes M. see Massa G.
Mahoudeau J. see Reznik Y.
Majeed-Saidan M.A., Joyce B., Khan M. & Hamam H.D. Congenital hypothyroidism: the Riyadh Military Hospital experience 191
Malerbi D.A., Mendonça B.B., Liberman B., Toledo S.P.A., Corradini M.C.M., Cunha-Neto M.B., Fragoso M.C.B.V. & Wajchenberg B.L. The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome 463
Malhotra A., Poon E., Tse W.-Y., Pringle P.J., Hindmarsh P.C. & Brook C.G.D. The effects of oxandrolone on the growth hormone and gonadal axes in boys with constitutional delay of growth and puberty 393
Mandard J.C. see Reznik Y.
Maruyama M., Sugenoya A., Kobayashi S., Masuda H., Shimizu T. & Iida F. Case of the Month A case of papillary carcinoma of the thyroid with more than 30 years long-term asymptomatic pulmonary metastases 331
Masala M. see Papini E.
Mashiach S. see Schiff E.
Massa G., Maes M., Heinrichs C., Vandeweghe M., Craen M. & Vanderschueren-Lodeweyckx M. Influence of spontaneous or induced puberty on the growth promoting effect of treatment with growth hormone in girls with Turner's syndrome 253
Massa G., Vanderscheuren-Lodeweyckx M. & Bouillon R. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone 137
Masson E.A., Atkin S.L., Diver M. & White M.C. Case of the Month Pituitary apoplexy and sudden blindness following the administration of gonadotrophin releasing hormone 109
Masuda H. see Maruyama M.
Mather S.J. see Ure E.
Matoth I. see Landau H.
Matthews D.R. see Bridges N.A.
Matthews D.R. see Pal B.R.
Matthews D.R. see Perros P.
Mau M., Phillips T.M. & Ratner R.E. Presence of anti-pituitary hormone antibodies in patients with empty sella syndrome and pituitary tumours 495
McArdle C. see Gallacher S.J.
McCance D.R., Gordon D.S., Fannin T.F., Hadden D.R., Kennedy L., Sheridan B. & Atkinson A.B. Assessment of endocrine function after transsphenoidal surgery for Cushing's disease 79
McHardy K.C. see MacLeod J.M.
McNicol A.M. see Gallacher S.J.
Méchain C., Cédrin I., Pandian C. & Lemay A. Serum FSH bioactivity and response to acute gonadotrophin releasing hormone (GnRH) agonist stimulation in patients with polycystic ovary syndrome (PCOS) as compared to control groups 311
Medlej R. see Lobaccaro J.-M.
Mendonça B.B. see Malerbi D.A.
Messinis I.E., Koutsoyiannis D., Milingos S., Tsahalina E., Seferiadis K., Lolis D. & Templeton A.A. Changes in pituitary response to GnRH during the luteal-follicular transition of the human menstrual cycle 159
Metcalfe K.A. see Williams D.J.
Michael A.E., Pester L.A., Curtis P., Shaw R.W., Edwards C.R.W. & Cooke B.A. Rapid communication Direct inhibition of ovarian steroidogenesis by cortisol and the modulatory role of 11β-hydroxysteroid dehydrogenase 641
Milingos S. see Messinis I.E.
Mitsuda N. see Kimura M.
Miura K. see Konno N.
Miura S. see Mune T.
Mixson A.J., Renault J.C., Ransom S., Bodenner D.L. & Weintraub B.D. Rapid communication Identification of a novel mutation in the gene encoding the β-triiodothyronine receptor in a patient with apparent selective pituitary resistance to thyroid hormone 227
Miyai K. see Kimura M.
Miyamoto T. see Sakurai A.
Modigliani E. see Casanova S.
Monson J.P. see Williams D.J.
Montgomery D. see Balen A.H.
Moreno-Reyes R., Boelaert M., El Badawi S., Eltom M. & Vanderpas J.B. Endemic hypothyroidism in a severe endemic goitre area of Sudan 17
Morita H. see Mune T.
Mullis P.E. see Pal B.R.
Mune T., Morita H., Yasuda K., Murayama M., Yamakita N. & Miura S. Elevated plasma 19-hydroxyandrostenedione levels in Cushing's disease: stimulation with ACTH and inhibition with metyrapone 265
Murakami S. see Konno N.
Murayama M. see Mune T.
Murray P.G. see Ginsberg J.
Muruais C. see Valcavi R.

Nairn E.R. see Gallacher S.J.
Nardi F. see Papini E.
Nielsen B. see Juul A.

Nieschlag E. Current therapy Care for the infertile male 123
Nikou A. see Tzanela M.
Nussey S. see Brada M.

O'Halloran D.J. see Dobrashian R.D.
Onaya T. see Wakasugi M.
Orri-Fend M. see Haase R.
Orsetti A. see Raynaud E.
Overstreet J.W. see Stewart D.R.

Pacella C.M. see Papini E.
Pache T.D. see Weber R.F.A.
Pagès J.Ch. see Raynaud E.
Pal B.R., Matthews D.R., Edge J.A., Mullis P.E., Hindmarsh P.C. & Dunger D.B. The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin dependent diabetes mellitus and are unaffected by short-tern euglycaemia 93
Pandian C. see Méchain C.
Panunzi C. see Papini E.
Papini E., Bacci V., Panunzi C., Pacella C.M., Fabbrini R., Bizzarri G., Petrucci L., Giammarco V., La Medica P., Masala M., Pitaro M. & Nardi F. A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules 507
Parry E.G. see Donald R.A.
Parton A. see Stewart P.M.
Paulsen O. see Fjellstad-Paulsen A.
Peñalva A., Pombo M., Carballo A., Barreiro J., Casanueva F.F. & Dieguez C. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6 87
Penn R. see Stewart P.M.
Pepys M.B. see Bristow A.F.
Perros P., Crombie A.L., Matthews D.R. & Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid–eye clinic 367
Pester L.A. see Michael A.E.
Peters J.R. see Ismail I.S.
Petrucci L. see Papini E.
Pfingsten H. see Haase R.
Phillips T.M. see Mau M.
Philokiprou D. see Tzanela M.
Pitaro M. see Papini E.
Plowman P.N. see Walker J.D.
Pombo M. see Peñalva A.
Poon E. see Malhotra A.
Portioli I. see Valcavi R.
Pouilles J.M. see Trémollières F.
Preece M.A. see Barton J.S.
Pringle P.J. see Bridges N.A.
Pringle P.J. see Malhotra A.
Proeschel M.F. see Favrod-Coune C.
Pumar A. see Leal-Cerro A.

Rachmilewitz E.A. see Landau H.
Rajan B. see Brada M.
Rajkovic I.A. see Ho K.K.Y.
Ransom S. see Mixson A.J.
Ratcliffe J.G. see Stewart P.M.
Ratcliffe W.A. see Bowden S.J.
Ratner R.E. see Mau M.
Raux-Demay M.C. see Favrod-Coune C.
Raynaud E., Audran M., Pagès J.Ch., Fédou C., Brun J.F., Chanal J.L. & Orsetti A. Determination of urinary testosterone and epitestosterone during pubertal development: a cross-sectional study in 141 normal male subjects 353
Reid I.W. see MacLeod J.M.
Reid R.W. see Balen A.H.
Reinwein D. see Haase R.
Renault J.C. see Mixson A.J.
Reznik Y., Rieu M., Kuhn J.M., Mandard J.C., Bottet P., Lemonnier D., Bekka S. & Mahoudeau J. Luteinizing hormone regulation by sex steroids in men with germinal and Leydig cell tumours 487
Ribot C. see Trémollières F.
Richards A.M. see Wittert G.A.
Rieu M. see Reznik Y.
Robert F. see Comtois R.
Robertson W.R. see Buckler H.M.
Robins S.P. see MacLeod J.M.
Roger M. see Lahlou N.
Rosén T., Bosaeus I., Tölli J., Lindstedt G. & Bengtsson B-Å. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency 63
Rosenberg-Bourgin M. see Casanova S.
Rothwell C. see Buckler H.M.
Rumsby G. & Honour J.W. Rapid communication Prenatal diagnosis of congenital adrenal hyperplasia by direct detection of mutations in the steroid 21-hydroxylase gene 421
Russell-Jones D.L., Weissberger A.J., Bowes S.B., Kelly J.M., Thomason M., Umpleby A.M., Jones R.H. & Sönksen P.H. Rapid communication The effects of growth hormone on protein metabolism in adult growth hormone deficient patients 427

Sakurai A., Miyamoto T., Hughes I.A. & DeGroot L.J. Characterization of a novel mutant human thyroid hormone receptor in a family with hereditary thyroid hormone resistance 29

Savage M.O. see Trainer P.J.
Scane A.C. & Francis R.M. Commentary Risk factors for osteoporosis in men 15
Scanlon M.F. see Ismail I.S.
Schachter M.E. see Balen A.H.
Schiff E., Ben-Baruch G., Galron R., Mashiach S. & Sokolovsky M. Endothelin-1 receptors in the human myometrium: evidence for different binding properties in post-menopausal as compared to premenopausal and pregnant women 321
Schoemaker J. see Broekmans F.J.
Schulte H.M. see Haase R.
Seferiadis K. see Messinis I.E.
Seppälä M. see Angervo M.
Seret-Bégué D. see Lahlou N.
Shalet S.M. see Buckler H.M.
Shalet S.M. see Dobrashian R.D.
Shaw R.W. see Michael A.E.
Sheppard M.C. see Franklyn J.A.
Sheridan B. see McCance D.R.
Shimizu T. see Maruyama M.
Short F. see Carey A.H.
Skakkebæk N.E. see Juul A.
Skingle L. see Williams D.J.
Smith J.F. Commentary The pathological diagnosis of carcinoma of the parathyroid 662
Sokolovsky M. see Schiff E.
Solomon B.L., Wartofsky L. & Burman K.D. Adjunctive cholestyramine therapy for thyrotoxicosis 39
Somma M. see Comtois R.
Sonino N., Fava G.A. & Boscaro M. A role for life events in the pathogenesis of Cushing's disease 261
Sönksen P.H. see Russell-Jones D.L.
Sönksen P.H. see Walker J.D.
Stewart D.R., Overstreet J.W., Celniker A.C., Hess D.L., Cragun J.R., Boyers S.P. & Lasley B.L. The relationship beetween hCG and relaxin secretion in normal pregnancies *vs* peri-implantation spontaneous abortions 379
Stewart P.M. Commentary Reproduction and the shuttle 645
Stewart P.M., Penn R., Holder R., Parton A., Ratcliffe J.G. & London D.R. The hypothalamo–pituitary–adrenal axis across the normal menstrual cycle and in polycystic ovary syndrome 387
Stock A.I. see Williams D.J.
Sugenoya A. see Maruyama M.
Sulmont V. see Grulet H.
Sultan C. see Lobaccaro J.-M.

Taguchi H. see Konno N.
Taguchi S. see Konno N.
Tamaki H. see Kimura M.
Tanizawa O. see Kimura M.
Tawata M. see Wakasugi M.
Templeton A.A. see Messinis I.E.
Tennent G.A. see Bristow A.F.
Thakker R.V. Review The molecular genetics of the multiple endocrine neoplasia syndrome 1
Thalassinos N.C. see Tzanela M.
Thomason M. see Russell-Jones D.L.
Thompson G.R. Current therapy Treatment of hyperlipidaemia 337
Tiihonen M. Angervo M.
Tims T. see Juul A.
Toft A.D. Commentary Fine-tuning of thyroxine replacement therapy 451
Toledo S.P.A. see Malerbi D.A.
Tölli J. see Rosén T.
Tovanabutra S., Illingworth P.J., Ledger W.L., Glasier A.F. & Baird D.T. The relationship between peripheral immunoactive inhibin, human chorionic gonadotrophin, oestradiol and progesterone during human pregnancy 101
Trainer P.J. see Walker J.D.
Trainer P.J., Lawrie H.S., Verhelst J., Howlett T.A., Lowe D.G., Grossman A.B., Savage M.O., Afshar F. & Besser G.M. Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment 73
Traish D. see Brada M.
Trémollières F., Pouilles J.M. & Ribot C. Effect of long-term administration of progestogen on post-menopausal bone loss: result of a two-year controlled randomized study 627
Tsahalina E. see Messinis I.E.
Tse W.-Y. see Malhotra A.
Tzanela M., Thalassinos N.C., Nikou A., Georgiadis G. & Philokiprou D. Effect of ^{131}I treatment on the calcitonin response to calcium infusion in hyperthyroid patients 25

Umpleby A.M. see Russell-Jones D.L.
Ur E. see Walker J.D.
Ure E., Bomanji J., Mather S.J., Britton K.E., Wass J.A.H., Grossman A.B. & Besser G.M. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogue, ^{123}I-Tyr-octreotide and ^{111}In-pentatreotide 501
Uttley D. see Brada M.

Valcavi R., Dieguez C., Zini M., Muruais C., Casanueva F. & Portioli I. Influence of hypothyroidism on growth hormone secretion 515
Välimäki M. see Angervo M.
Valiontis E. see Ho K.K.Y.

Vanderpas J.B. see Moreno-Reyes R.
Vanderscheuren-Lodeweyckx M. see Massa G.
Vandeweghe M. see Massa G.
Verhelst J. see Trainer P.J.
Verhoeff N.P.L.G. see Assies J.
Villamil F. see Leal-Cerro A.
Vis H.L. see Heinrichs C.

Wajchenberg B.L. see Malerbi D.A.
Wakao R. see Wakasugi M.
Wakasugi M., Wakao R., Tawata M., Gan N., Koizumi K. & Onaya T. Bone mineral density in patients with hyperthyroidism measured by dual energy X-ray absorptiometry 283
Walker J.D., Grossman A., Anderson J.V., Ur E., Trainer P.J., Benn J., Lowy C., Sönksen P.H., Plowman P.N., Lowe D.G., Doniach I., Wass J.A.H. & Besser G.M. Malignant prolactinoma with extracranial metastases: a report of three cases 411
Warnet A. see Lahlou N.
Wartofsky L. see Solomon B.L.
Wass J.A.H. see Cotterill A.M.
Wass J.A.H. see Ure E.
Wass J.A.H. see Walker J.D.
Waters M.J. see Ho K.K.Y.
Watkins P.J. see Drury P.L.
Weber R.F.A., Pache T.D., Jacobs M.L., Docter R., Loriaux D.L., Fauser B.C.J.M. & Birkenhäger J.C. The relation between clinical manifestations of polycystic ovary syndrome and β-cell function 295
Weintraub B.D. see Mixson A.J.
Weissberger A.J. see Russell-Jones D.L.
Wheeler M.J. Commentary Methods for the detection of testosterone abuse in athletes 351
White D. see Carey A.H.
White M.C. see Masson E.A.
Williams D.J., Metcalfe K.A., Skingle L., Stock A.I., Beedham T. & Monson J.P. Pathophysiology of transient cranial diabetes insipidus during pregnancy 595
Williams R. see Cundy T.
Williamson R. see Carey A.H.
Wittert G.A. see Donald R.A.
Wittert G.A., Espiner E.A., Richards A.M., Donald R.A., Livesey J.H. & Yandle T.G. Atrial natriuretic factor reduces vasopressin and angiotensin II but not the ACTH response to acute hypoglycaemic stress in normal men 183
Wong D. see Conway G.S.

Yamakita N. see Mune T.
Yandle T. see Donald R.A.
Yandle T.G. see Wittert G.A.
Yasuda K. see Mune T.
Yuri K. see Konno N.

Zini M. see Valcavi R.

Clinical Endocrinology (1993) **38**, 677–680

Subject index to Volume 38

Abortions
  hCG and relaxin 379
Acromegaly
  IGF-I and LH levels following glucose 589
ACTH
  and 19-OH-androstenedione in Cushing's disease 265
ANF
  effect on vasopressin, angiotensin II and ACTH response to hypoglycaemia 183
Anorchia
  the SRY gene 197
Anti-pituitary hormone antibodies
  empty sella and pituitary tumours 495
Athletes
  testosterone abuse (Commentary) 351, 353

Baldness
  male pattern and PCOS, genetics (Rapid communication) 653
β-cell function
  and PCOS 295
Blindness
  and pituitary apoplexy after GnRH (Case of the Month) 109
Blood pressure
  and renin–angiotensin–aldosterone and rhGH in children 245
Body composition
  in GH deficiency 63
Bone
  osteoporosis in men (Commentary) 15
  turnover, effects of ^{131}Ion in hyperthyroidism 49
  mineral density measurement 283
  loss, post-menopausal, and progestogen 627
Bromocriptine
  control of PRL-secreting macroadenomas 165

CAH
  prenatal genetic diagnosis (Rapid communication) 421
Calcitonin
  response to Ca infusion in hyperthyroidism, effect of ^{131}I 25
Calcium
  infusion in hyperthyroidism, effect of ^{131}I on calcitonin response 25
Children
  iodine deficiency and goitre (Commentary) 17, 19
  rhGH treatment and GH antibodies 137
  rhGH treatment and blood pressure and renin–angiotensin–aldosterone 245
  puberty, growth and rhGH in girls with Turner's syndrome 253
  effect of oxandrolone in CDGP 393
  IGF-I in GH insensitive (Laron) (Rapid communication) 647
Cholecystectomy
  conventional and laparoscopic 609
Cholestyramine
  adjunctive therapy for thyrotoxicosis 39
Cholinergic control
  of GH response to GHRH in IDDM 149
Coronary heart disease
  hyperlipidaemia (Current therapy) 337
Cortisol
  11β-HSD and ovarian steroidogenesis (Rapid communication) 641, (Commentary) 645
oCRH
  test potentiation by lysine vasopressin 405
Cushing's disease
  cortisol level after transsphenoidal resection 73
  endocrine function after transsphenoidal surgery 79
  pathogenesis and life events 261
  19-OH-androstenedione levels 265
  GHRH effects on GH secretion 399
  desmopressin in diagnosis (Commentary) 461, 463
  PRL levels without pituitary adenoma 601

1-Deamino-8-D-arginine vasopressin pharmacokinetics 177
Desmopressin
  in Cushing' diagnosis (Commentary) 461, 463
Diabetes
  prevention of nephropathy (Review) 445
  cranial in pregnancy 595
Drug abuse
  testosterone in athletics (Commentary) 351, 353

Empty sella syndrome
  anti-pituitary hormone antibodies and pituitary tumours 495
Endothelin-1 receptors
  binding properties in myometrium 321

FSH
  in ovulation induction in PCOS 209
  and gonadotroph adenoma volume in men 301
  response to GhRH in PCOS 311

Genetics
  molecular of MEN (Review) 1
  mutant thyroid hormone receptor β 29
  congenital hypothyroidism 191
  the SRY gene in anorchia 197
  mutation in gene encoding β-triiodothyronine receptor

Genetics (*contd*)
in pituitary resistance to thyroid hormone (Rapid communication) 227, (Commentary) 235
prenatal diagnosis of CAH (Rapid communication) 421
haemochromatosis and hypogonadotrophic hypogonadism 617
in PCOS and male pattern baldness (Rapid communication) 653
Germinal cell tumours
LH regulation by sex steroids in men 487
GH
deficiency, body fat and extracellular fluid 63
response to GHRP-6 87
secretory episodes analysis in IDDM and euglycaemia 93
heterogeneity (Review) 113
treatment and GH antibodies in children 137
mode of treatment and GHBP activity 143
deficiency and impaired thermoregulation (Rapid communication) 237
rhGH and blood pressure, renin–angiotensin–aldosterone in children 245
rhGH, puberty and growth in girls with Turner's syndrome 253
secretion and GHRH in Cushing's disease 399
effect on protein metabolism in GH deficiency (Rapid communication) 427
secretion in hyperthyroidism 515
and IGF-I levels following glucose in acromegaly 589
GH antibodies
and rhGH treatment in children 137
GHBP
activity and GH treatment 143
GHRH
and GH secretion in Cushing's disease 399
GHRP-6
and GH response 87
GnRH
and pituitary apoplexy and blindness (Case of the Month) 109
effect on pituitary during luteal–follicular transition 159
and FSH response in PCOS 311
Goitre
and iodine deficiency in children (Commentary) 17, 19
Gonadotroph adenoma
volume and inhibin and FSH in men 301

Haemochromatosis
genetic and hypogonadotrophic hypogonadism 617
hCG
in pregnancy 101
and relaxin in pregnancy and abortions 379
hMG
self-administration for testicular growth and spermatogenesis in hypogonadotrophic hypogonadism 203
11β-HSD
cortisol and ovarian steroidogenesis (Rapid communication) 641, (Commentary) 645
Hypercalcaemia
and hyperparathyroidism (Case of the Month) 433
Hyperemesis gravidarum
hCG and thyrotoxicosis (Commentary) 343, 345
Hyperlipidaema
(Current therapy) 337
Hyperparathyroidism
and cancer-associated hypercalcaemia (Case of the Month) 433
US guided chemical parathyroidectomy 523
Hyperthyroidism
effect of ^{131}I on calcitonin response to Ca infusion 25
effect of ^{131}I on bone turnover 49
BMD measurement 283
and GH secretion 515
Hypoglycaemia
effect of ANF on AVP, angiotensin II and ACTH 183
Hypogonadism
male (Current therapy) 123
self-administration of hMG 203
testicular growth, spermatogenesis and GnRH 473
and genetic haemochromatosis 617
Hypothyroidism
congenital 191

IDDM
analysis of GH secretory episodes 93
cholinergic control of GH response to GHRH 149
IGF-I
and GH levels following glucose in acromegaly 589
in GH insensitive (Laron) children (Rapid communication) 647
IGFBP-1
levels and thyroxin (Rapid communication) 547
and insulin secretion following hypoglycaemia 633
Infertility
male (Current therapy) 123
Inhibin
in pregnancy 101
and gonadotroph adenoma volume in men 301
Insulin
by IRMA in PCOS 219
resistance and LH in PCOS 621
secretion and IGFBP-1 following hypoglycaemia 633
Iodine-131
effect on calcitonin response to Ca in hyperthyroidism 25
effects on bone turnover in hyperthyroidism 49

Iodine deficiency
and goitre in children (Commentary) 17, 19

Kidney disease
diabetic, prevention (Review) 445

Laron syndrome
IGF-I in children (Rapid communication) 647
Leydig cell tumours
LH regulation by sex steroids in men 487
LH
heterogeneity (Review) 113
bio to immuno ratio and oestradiol in women 481
regulation by sex steroids in men with germinal and Leydig cell tumours 487
release and triptorelin GnRH agonist 579
and insulin resistance in ICOS 621
Lysine vasopressin
potentiation of oCRH test 405

Macroadenomas
PRL-secreting, control by bromocriptine 165
Men
osteoporosis in (Commentary) 15
infertility (Current therapy) 123
self administration of hMG in hypogonadotrophic hypogonadism 203
inhibin, FSH and gonadotroph adenoma volume 301
PCO in untreated female to male transsexuals 325
testosterone abuse in athletes (Commentary) 351, 353
endogenous testosterone and gonadotrophin secretion 373
testicular growth, spermatogenesis and GnRH in hypogonadotrophic hypogonadism 473
LH regulation by sex steroids with germinal and Leydig cell tumours 487
MEN
molecular genetics (Review) 1
phaeochromocytoma 531
Metastases
pulmonary and thyroid carcinoma (Case of the Month) 331, (Commentary) 336
extracranial and prolactinoma 411
Metyrapone
and 19-OH-androstenedione in Cushing's disease 265
Myometrium
endothelin-1 receptor binding 321

Nephropathy
diabetic, prevention (Review) 445
Neuroendocrine tumours
localization by radiolabelled somatostatin analogues 501

Oestradiol
in pregnancy 101
and bio to immuno LH ratio in women 481
Ophthalmopathy
thyroid-associated, age and gender 367
Osteoporosis
in men (Commentary) 15
Ovarian steroidogenesis
cortisol and 11β-HSD (Rapid communication) 641, (Commentary) 645
Oxandrolone
effect on CDGP in boys 393

Parathyroid carcinoma
(Case of the Month) 659, (Commentary) 662
Parathyroidectomy
chemical, US guided in hyperparathyroidism 523
PCOS
FSH in ovulation induction 209
IRMA for insulin 219
and β-cell function 295
FSH response to GnRH 311
in untreated female to male transsexuals 325
h-p-a axis 387
LH and insulin resistance 621
and male pattern baldness, genetics (Rapid communication) 653
Pentatreotide
^{111}In-labelled and neuroendocrine tumour localization 501
Pirenzepine
and pyridostigmine control of GH response to GHRH in IDDM 149
Phaeochromocytoma
in MEN-2A 531
Pituitary apoplexy
and blindness after GnRH (Case of the Month) 109
Pituitary resistance to thyroid hormone
gene mutation (Rapid communication) 227, (Commentary) 235
Pituitary tumours
anti-pituitary hormone antibodies and empty sella 495
adenomas, pathogenesis (Review) 559
adenomas, conservative surgery and radiotherapy 571
Pregnancy
inhibin, hCG, E_2 and progesterone 101
endothelin-1 receptor binding in myometrium 321
hyperemesis gravidarum, hCG and thyrotoxicosis 343, 345
hCG and relaxin, and in abortions 379
prenatal genetic diagnosis of CAH (Rapid communication) 421
and cranial diabetes 595

PRL
secretion, control by bromocriptine 165
levels in Cushing's disease without pituitary adenoma 601
Progesterone
in pregnancy 101
and post-menopausal bone loss 627
Prolactinoma
with extracranial metastases 411
with intracranial metastases (Case of the Month) 539
Protein
metabolism, effect of GH in GH deficiency (Rapid communication) 427
Protein kinase C
effects of TSH receptor antibodies in thyroid 45
PTHrP
(Commentary) 135
molecular forms 287
Pulmonary metastases
and thyroid carcinoma (Case of the Month) 331, (Commentary) 336
Pyridostigmine
and pirenzepine control of GH response to GHRH in IDDM 149

Renal disease
diabetic, prevention (Review) 445

Somatostatin analogues
radiolabelled and neuroendocrine tumour localization 501

Testes
maldescended (Current therapy) 123
growth, spermatogenesis and GnRH in hypogonadotrophic hypogonadism 473
Testosterone
abuse in athletes (Commentary) 351, 353
endogenous and gonadotrophin secretion 373
Thalassaemia major
pituitary–thyroid axis 55
Thermoregulation
impaired in GH deficiency (Rapid communication) 237
Thyroid
effects of TSH receptor antibodies on protein kinase C 45
disease, screening 273
papillary carcinoma with pulmonary metastases (Case of the Month) 331, (Commentary) 336
nodules and L-thyroxine 507
Thyroid hormone resistance
mutant thyroid hormone receptor β gene (Rapid communication) 227, (Commentary) 235
Thyrotoxicosis
adjunctive cholestyramine therapy 39
hCG and hyperemesis gravidarum (Commentary) 343, 345
ophthalmopathy, age and gender 367
Thyroxine
for solitary thyroid nodules 507
and IGFBP-1 levels (Rapid communication) 547
Thyroxine binding globulin
International Standard 361
Thyroxine replacement
(Commentary) 451, 453
Transsexuals
PCO in untreated female to male 325
Triptorelin
GnRH agonist and LH release 579
TSH receptor antibodies
effects on protein kinase C 45
Turner's syndrome
puberty, growth and rhGH in girls 253

Ultrasound
guided chemical parathyroidectomy 523

Varicocele
(Current therapy) 123
Vasopressin, 1-deamino-8-D-arginine
pharmacokinetics 177

Women
inhibin, hCG, E_2 and progesterone in pregnancy 101
pituitary response to GnRH during luteal–follicular transition 159
FSH in ovulation induction in PCOS 209
IRMA for insulin in PCOS 219
PCOS and β-cell function 295
FSH response to GnRH in PCOS 311
endothelin-1 receptor binding properties in myometrium 321
PCO in untreated female to male transsexuals 325
hCG, thyrotoxicosis and hyperemesis gravidarum (Commentary) 343, 345
hCG and relaxin in pregnancy and abortions 379
h-p-a axis in PCOS 387
prenatal genetic diagnosis of CAH (Rapid communication) 421
bio to immuno LH ratio and oestradiol 481
cranial diabetes in pregnancy 595
LH and insulin resistance in PCOS 621
progestogen and bone loss 627
ovarian steroidogenesis, cortisol and 11β-HSD (Rapid communication) 641, (Commentary) 645
PCOS and male pattern baldness (Rapid communication) 653